Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cephalexin every other day versus daily prophylaxis in children with vesicoureteral reflux
IRCT20250412065295N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of cefalexin in vesicoureteral reflux (VUR) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Age, Gender and 4 more. Started May 2025; status: completed.
02
Drugs
cefalexin
03
Conditions
vesicoureteral reflux (VUR)
Beyond the preview
Go deeper on IRCT20250412065295N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250412065295N1.